Altered Localization of Retinoid X Receptor α Coincides with Loss of Retinoid Responsiveness in Human Breast Cancer MDA-MB-231 Cells

Author:

Tanaka T.1,Dancheck B. L.1,Trifiletti L. C.1,Birnkrant R. E.1,Taylor B. J.1,Garfield S. H.1,Thorgeirsson U.1,De Luca L. M.1

Affiliation:

1. National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255

Abstract

ABSTRACT To understand the mechanism of retinoid resistance, we studied the subcellular localization and function of retinoid receptors in human breast cancer cell lines. Retinoid X receptor α (RXRα) localized throughout the nucleoplasm in retinoid-sensitive normal human mammary epithelial cells and in retinoid-responsive breast cancer cell line (MCF-7), whereas it was found in the splicing factor compartment (SFC) of the retinoid-resistant MDA-MB-231 breast cancer cell line and in human breast carcinoma tissue. In MDA-MB-231 cells, RXRα was not associated with active transcription site in the presence of ligand. Similarly, ligand-dependent RXR homo- or heterodimer-mediated transactivation on RXR response element or RARE showed minimal response to ligand in MDA-MB-231 cells. Infecting MDA-MB-231 cells with adenoviral RXRα induced nucleoplasmic overexpression of RXRα and resulted in apoptosis upon treatment with an RXR ligand. This suggests that nucleoplasmic RXRα restores retinoid sensitivity. Epitope-tagged RXRα and a C-terminus deletion mutant failed to localize to the SFC. Moreover, RXRα localization to the SFC was inhibited with RXRα C-terminus peptide. This peptide also induced ligand-dependent transactivation on RXRE. Therefore, the RXRα C terminus may play a role in the intranuclear localization of RXRα. Our results provide evidence that altered localization of RXRα to the SFC may be an important factor for the loss of retinoid responsiveness in MDA-MB-231 breast cancer cells.

Publisher

American Society for Microbiology

Subject

Cell Biology,Molecular Biology

Reference57 articles.

1. Bischoff, E. D., M. M. Gottardis, T. E. Moon, R. A. Heyman, and W. W. Lamph. 1998. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 58 : 479-484.

2. Boccardo, F., L. Canobbio, M. Resasco, A. U. Decensi, G. Pastorino, and F. Brema. 1990. Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol. 116 : 503-506.

3. Cassidy, J., M. Lippman, A. Lacroix, and G. Peck. 1982. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 18 : 925-928.

4. Castelein, H., P. E. Declercq, and M. Baes. 1997. DNA binding preferences of PPAR alpha/RXR alpha heterodimers. Biochem. Biophys. Res. Commun. 233 : 91-95.

5. Chen, A. C., X. Guo, F. Derguini, and L. J. Gudas. 1997. Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res. 57 : 4642-4651.

Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3